These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26264211)

  • 1. STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
    Permuth-Wey J; Fulp WJ; Reid BM; Chen Z; Georgeades C; Cheng JQ; Magliocco A; Chen DT; Lancaster JM
    Int J Cancer; 2016 Feb; 138(3):612-9. PubMed ID: 26264211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
    Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
    Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.
    Lawrenson K; Iversen ES; Tyrer J; Weber RP; Concannon P; Hazelett DJ; Li Q; Marks JR; Berchuck A; Lee JM; Aben KK; Anton-Culver H; Antonenkova N; ; ; Bandera EV; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Chang-Claude J; Chenevix-Trench G; Chen A; Chen Z; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Plisiecka-Halasa J; Dennis J; Dicks E; Doherty JA; Dörk T; du Bois A; Eccles D; Easton DT; Edwards RP; Eilber U; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goode EL; Goodman MT; Gronwald J; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall E; Hogdall C; Hosono S; Jakubowska A; Paul J; Jensen A; Karlan BY; Kjaer SK; Kelemen LE; Kellar M; Kelley JL; Kiemeney LA; Krakstad C; Lambrechts D; Lambrechts S; Le ND; Lee AW; Cannioto R; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; Nevanlinna H; McNeish I; Menon U; Modugno F; Moysich KB; Narod SA; Nedergaard L; Ness RB; Noor Azmi MA; Odunsi K; Olson SH; Orlow I; Orsulic S; Pearce CL; Pejovic T; Pelttari LM; Permuth-Wey J; Phelan CM; Pike MC; Poole EM; Ramus SJ; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Budzilowska A; Sellers TA; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Sucheston L; Tangen IL; Teo SH; Terry KL; Thompson PJ; Timorek A; Tworoger SS; Van Nieuwenhuysen E; Vergote I; Vierkant RA; Wang-Gohrke S; Walsh C; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Woo YL; Wu X; Wu AH; Yang H; Zheng W; Ziogas A; Coetzee GA; Freedman ML; Monteiro AN; Moes-Sosnowska J; Kupryjanczyk J; Pharoah PD; Gayther SA; Schildkraut JM
    Carcinogenesis; 2015 Nov; 36(11):1341-53. PubMed ID: 26424751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
    Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
    Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction value of intercellular adhesion molecule-1 gene polymorphisms for epithelial ovarian cancer risk, clinical features, and prognosis.
    Cai G; Ma X; Zou W; Huang Y; Zhang J; Wang D; Chen B
    Gene; 2014 Aug; 546(1):117-23. PubMed ID: 23933413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.
    Li H; Dai H; Shi T; Cheng X; Sun M; Chen K; Wang M; Wei Q
    Carcinogenesis; 2020 Sep; 41(9):1229-1237. PubMed ID: 32663249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.